CVS Caremark Announces First 13 Drugs to be Incorporated Into Their “Genetic Benefit Management Service”
Posted Jun 02 2010 3:18pm
Generation Health has put together a "Best Test" laboratory network to manage testing costs for payers. The firm has also developed data and analytics to review gaps in care among patients, and outreach programs addressing communications between patients, physicians and pharmacists. This is a focus toward employers and is cost related, so I guess now we can add on genetic testing benefit managers to work with pharmacy benefit managers.
“This is the first announcement of this type I have seen. Generation Health bills itself as a genetic benefit management company. It seems interesting that GINA has just become effective with new provisions that prevent family history to be used as it relates back to potential discrimination in hereditary areas and now we have a company wanting to jump in and help patients manage clinical and genetic testing through a pharmacy benefit manager. “
As noted before, the box will not be available on the shelf. With the announcement of these first 3 drugs they will council on whether or not the particular drugs will work. As I understand this is being generated via the employer benefit manager with health insurance benefits. BD
NEW YORK (GenomeWeb News) – CVS Caremark and Generation Health today announced the 13 drug therapies that will be included in the initial offering of their integrated Genetic Benefit Management service.
The firms said that they are offering the industry's first Best Test Genetics Network, which coordinates pharmacogenomic testing for members of CVS Caremark's network.
The drugs that have been selected thus far include six drugs dispensed generally through PBM services: Nolvadex (tamoxifen), Plavix (clopidogrel), Tabloid (thioguanine), Tegretol (carbamazepine), and Ziagen (abacavir).
It also includes seven drugs dispensed through CVS Caremark's specialty pharmacy business: Pegasys (peginterferon alfa-2a), Copegus (ribavirin), Gleevec (imatinib mesylate), Tasigna (nilotinib), Sprycel (dasatinib), Tarceva (erlotinib), and Tykerb (lapatinib).
Through its PGx testing program, CVS Caremark hopes to manage costs and improve healthcare outcomes through its more than 7,000 CVS pharmacy and Longs Drugs stores; its PBM, mail order, and specialty pharmacy arm Caremark Pharmacy Services; its retail-based health clinic subsidiary MinuteClinic; and its online pharmacy, CVS.com. The PBM division, Caremark Pharmacy Services, provides services to more than 2,000 health plans.